Morepen Laboratories Ltd (MOREPENLAB) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Morepen Laboratories experienced a 7.4% YoY increase in revenue, reaching INR 1,830 crores, driven by growth in both Pharma and Medical Devices segments.
- The company maintains market leadership in six APIs and two medical devices (glucometers and BP monitors).
- Exports constitute 72% of the Pharma business, contributing to high-value earnings.
- Formulation business (Rx and OTC) is a growing focus area, with plans to expand the sales team significantly.
- Medical devices business witnessed a 12% YoY revenue growth, reaching INR 496 crores.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.